FDA staffers sing Pfizer/BioNTech COVID shot's praises ahead of key committee meeting How will the distribution work for new COVID-19 vaccine? Here are some of the details Not enough Pfizer vaccine doses? Blame the feds, not the company: reports Nursing home organizations call for long-term care residents, staff to be first in line for COVID-19 vaccine Forbion raises €460M in weeks to back next crop of EU biotechs Biopharma roundup: Pfizer vaccine wins early FDA praise; AstraZeneca inks shot manufacturing deal Sinovac snags $515M investment to double COVID-19 vaccine capacity as phase 3 readout nears U.S. agency behind Kodak's beefy drug manufacturing loan played by the books, investigation finds: report Featured Story | By Angus Liu The FDA has released its internal review documents ahead of the closely watched COVID-19 vaccine advisory committee meeting scheduled for Thursday—and they bode well for Pfizer and partner BioNTech's prospects for securing a quick emergency use authorization. read more |
| |
|---|
|
Top Stories By Tina Reed At a "Vaccine Summit" to be hosted by the White House Tuesday, officials are expected to dive deeper into the details of the COVID-19 vaccine plan. Here's a rundown of some of the early details. read more By Arlene Weintraub Pfizer reportedly urged U.S. government officials to pre-order more than 100 million doses of its COVID-19 vaccine, but they declined, raising new questions about whether there will be enough shots to ensure a broad and quick rollout stateside if the FDA grants an emergency use authorization soon. read more By Tina Reed That includes putting them ahead of others who've also been identified as a top priority for vaccinations by a Centers for Disease Control and Prevention panel, such as front-line healthcare workers, officials said. read more By Nick Paul Taylor Forbion has raised a €460 million ($558 million) early-stage venture capital fund. The fund hit its hard cap weeks after opening, adding further evidence of the willingness of investors to back experienced European VC shops. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner The FDA is already buzzing about Pfizer and BioNTech's vaccine. Plus, AstraZeneca's shot is still safe and effective, Lancet researchers confirmed. AZ tapped Halix to perform commercial vaccine production in the Netherlands. NeuroRx and Relief recruited enough subjects for their phase 2b/3 aviptadil trial. And the agency behind Kodak's controversial manufacturing loan has been absolved. read more By Angus Liu As different COVID-19 vaccines move closer to the finish line, their developers have been raising money from investors or through advance government purchases to ramp up manufacturing. Now, China's Sinovac has done the same for its phase 3 candidate, netting $515 million to double its capacity. read more By Fraiser Kansteiner The Inspector General of the U.S. International Development Finance Corporation, which brokered Eastman Kodak’s ill-fated loan to jump into drug manufacturing, cleared agency officials of any wrongdoing. One thing that could have used some work, though? The timing of the deal's announcement. read more |
